

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED**

### **華康生物醫學控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 8622)**

## **POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON 15 JANUARY 2026**

The Board is pleased to announce that the resolution proposed at the EGM held on 15 January 2026 was duly passed by the Shareholders by way of poll.

Reference is made to the notice (the “**Notice**”) of the extraordinary general meeting (the “**EGM**”), the circular of Huakang Biomedical Holdings Company Limited (the “**Company**”) dated 22 December 2025 (the “**Circular**”) and the announcement of the Company dated 23 December 2025 on the postponement of the EGM and change of book closure period and record date in relation to the Proposed Change of Company Name. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

### **POLL RESULTS OF THE EGM**

The Board is pleased to announce that the resolution set out in the Notice was duly passed as special resolution by the Shareholders by way of poll at the EGM held on 15 January 2026. All Directors attended the EGM physically or via electronically means.

Tricor Investor Services Limited, the Company’s branch share registrar and transfer office in Hong Kong, was appointed and acted as the scrutineer for the purpose of vote-taking at the EGM.

The poll result in respect of the resolution proposed at the EGM is as follows:

Special Resolution	Number of Shares voted (percentage of total number of Shares voted)	
	For	Against
To approve the change of the English name of the Company from “Huakang Biomedical Holdings Company Limited” to “Joyzyme Group Limited” and adopt the Chinese name “愉悦集團有限公司” as its new dual foreign name to replace its existing Chinese name “華康生物醫學控股有限公司” with effect from the date of the certificate of incorporation on change of name issued by the Registrar of Companies of the Cayman Islands, and to authorise the directors of the Company to do all such acts, deeds and things and execute all such documents and make all such arrangements as he/she/they consider necessary, desirable or expedient for the purpose of, or in connection with, the implementation of and giving effect to the above proposed change of company name and to attend to any necessary registration and/or filing for and on behalf of the Company.	264,240,000 (100%)	0 (0%)

As more than 75% of the votes were cast in favour of the Resolution, the Resolution was duly passed as special resolution of the Company at the EGM.

As at the date of the EGM, the total number of issued Shares was 515,472,000 Shares, which was the total number of Shares entitling the Shareholders to attend and vote on the proposed resolution at the EGM. There were no restrictions on any Shareholders to cast votes on the proposed resolution at the EGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favour at the EGM as set out in rule 17.47A of the GEM Listing Rules. No Shareholder was required under the Articles or the GEM Listing Rules to abstain from voting at the EGM. None of the Shareholders has stated their intention in the Company’s circular dated 22 December 2025 to vote against or to abstain from voting on the resolution proposed at the EGM.

## GENERAL

Subsequent to the passing of the above special resolution by the Shareholders at the EGM, the Change of Company Name is still subject to the approval of the Registrar of Companies in the Cayman Islands by way of issue of the Certificate of Incorporation on Change of Name. Upon the Change of Company Name taking effect and the receipt of the Certificate of Incorporation on Change of Name from the Registrar of Companies in the Cayman Islands, the Company will carry out the necessary filing procedures with the Companies Registry in Hong Kong. The Company will make further announcement(s) on the effective date of the Change of Company Name and the change in the stock short names once the Change of Company Name becomes effective.

On behalf of the Board  
**Huakang Biomedical Holdings Company Limited**  
**Zhang Yujing**  
*Co-Chairman and Executive Director*

Hong Kong, 15 January 2026

*As at the date of this announcement, the Executive Directors are Ms. Zhang Yujing, Dr. Zhou Xunyong, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael; the Non-executive Directors are Dr. Bu Su and Dr. Xu Ming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Ms. Wang Yachun and Mr. Tsui Wing Tak.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the Stock Exchange website at [www.hkexnews.hk](http://www.hkexnews.hk) for at least seven days from the date of publication and on the Company’s website at [www.huakangbiomedical.com](http://www.huakangbiomedical.com).*